Fed. Circ. Upholds PTAB's Ax Of Novartis MS Drug Patent
The Federal Circuit on Wednesday affirmed the Patent Trial and Appeal Board's decision invalidating a patent covering Novartis' multiple sclerosis drug Gilenya, which had sales of $3.1 billion last year, in...To view the full article, register now.
Already a subscriber? Click here to view full article